Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5811/cpcem.2017.6.34356 http://scihub22266oqcxt.onion/10.5811/cpcem.2017.6.34356 C5965212!5965212!29849330     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Pract+Cases+Emerg+Med 2017 ; 1 (4): 349-53 Nephropedia Template TP {{tp|p=29849330|t=2017. Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage |pdf=|usr=}}{{29849330}} gab.com Text Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage JO: Clin Pract Cases Emerg Med http://www.kidney.de/pget.php?&tw=1&pmid=29849330 #FOAvip Dabigatran etexilate mesylate is a direct thrombin inhibitor used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Dabigatran belongs to a new generation of oral agents for anticoagulation ? the direct oral anticoagulants (DOACs). The DOACs also include the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. In the case of major or life-threatening bleeding and/or the need for emergent invasive procedures, a reversal agent is needed if a patient is taking one of these medications. Research has shown the efficacy of idarucizumab as an antidote in healthy volunteers, but data in the case of life-threatening bleeds remains limited. We report a case of a patient who suffered a traumatic subarachnoid hemorrhage and received effective treatment with idarucizumab. Along with other reports, our case demonstrates that dabigatran-related major and/or life-threatening bleeds may be effectively counteracted by idarucizumab. This provides an option to emergency department providers in managing clinically significant bleeds in patients taking dabigatran. Twit Text FOAVip Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage ????Clin Pract Cases Emerg Med http://www.kidney.de/pget.php?&tw=1&pmid=29849330 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29849330 #FOAvip English Wikipedia <ref>{{Cite pmid|29849330}}</ref> Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage #MMPMID29849330 Balakumar J; Santiago R; Supino M Clin Pract Cases Emerg Med 2017[Nov]; 1 (4): 349-53 PMID29849330show ga Dabigatran etexilate mesylate is a direct thrombin inhibitor used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Dabigatran belongs to a new generation of oral agents for anticoagulation ? the direct oral anticoagulants (DOACs). The DOACs also include the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. In the case of major or life-threatening bleeding and/or the need for emergent invasive procedures, a reversal agent is needed if a patient is taking one of these medications. Research has shown the efficacy of idarucizumab as an antidote in healthy volunteers, but data in the case of life-threatening bleeds remains limited. We report a case of a patient who suffered a traumatic subarachnoid hemorrhage and received effective treatment with idarucizumab. Along with other reports, our case demonstrates that dabigatran-related major and/or life-threatening bleeds may be effectively counteracted by idarucizumab. This provides an option to emergency department providers in managing clinically significant bleeds in patients taking dabigatran. äReversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrh(epmc).pdf DeepDyve Pubget Overpricing